source
- Amgen's Repatha shows reduced heart attack risk while Satellos alters Duchenne trial endpointSatellos Bioscience announced a change to the primary endpoint of its ongoing Duchenne muscular dystrophy trial of the investigational small‑molecule forazapadin, shifting focus to a measure of mus…
- Novartis reports seven tumor cases in children treated with ZolgensmaNovartis has disclosed that seven children who received its gene therapy Zolgensma for spinal muscular atrophy were later found to have tumors. The company said the cases were identified during po…